quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:51:07·10d
ANALYSTRating
Biohaven Ltd. logo

Canaccord Genuity initiated coverage on Biohaven with a new price target

BHVN· Biohaven Ltd.
Health Care
Original source

Companies

  • BHVN
    Biohaven Ltd.
    Health Care

Recent analyst ratings

  • Apr 13UpdateCanaccord Genuity$21.00
  • Feb 6UpdateGoldman$23.00
  • Jan 21UpdateRBC Capital Mkts$22.00
  • Dec 3UpdateH.C. Wainwright$11.00
  • Nov 26UpdateUBS$11.00
  • Nov 6UpdateBernstein$9.00

Related

  • INSIDER35d
    SEC Form 4 filed by Mehta Kishan
  • PR35d
    Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
  • SEC41d
    SEC Form DEFA14A filed by Biohaven Ltd.
  • SEC41d
    SEC Form DEF 14A filed by Biohaven Ltd.
  • INSIDER45d
    Amendment: Director Childs John W bought $864,115 worth of shares (28,400 units at $30.43) (SEC Form 4)
  • INSIDER51d
    SEC Form 4 filed by Chief Financial Officer Buten Matthew
  • INSIDER51d
    SEC Form 4 filed by SVP, Clinical Operations Gentile Kimberly
  • INSIDER51d
    SEC Form 4 filed by VP, Chief Accounting Officer Clark George C.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022